If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Orforglipron-Obesity
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.
What orforglipron clinical trials are being conducted in people with obesity or overweight?
The ATTAIN clinical trial program evaluates investigational doses of orforglipron for the treatment of obesity or overweight in adults with or without comorbidities.
ATTAIN Clinical Trial Program: Orforglipron for the Treatment of Obesity or Overweight
Orforglipron is a novel, once-daily, oral, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed for the treatment of obesity or overweight and the treatment of type 2 diabetes (T2D).1
The ATTAIN clinical trial program assesses the efficacy and safety of investigational doses of orforglipron as a treatment for obesity or overweight (Overview of the ATTAIN Phase 3 Clinical Trial Program of Orforglipron for the Treatment of Obesity or Overweight).
Trial and Target Population |
Key Inclusion Criteria |
Orforglipron Groups |
Comparator |
Primary Endpoint(s) |
Primary Timepoint |
Global Trials |
|||||
ATTAIN-12 |
|
Administered PO |
PBO |
Percent CFB in BW |
72 weeks |
ATTAIN-23 |
|
Administered PO |
PBO |
Percent CFB in BW |
72 weeks |
Regional Trials |
|||||
ATTAIN-J4 |
Administered PO |
PBO |
Percent CFB in BW |
72 weeks |
|
Abbreviations: BMI = body mass index; BW = body weight; CFB = change from baseline; PBO = placebo; PO = orally; T2D = type 2 diabetes.
aComorbidities included hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.
bComorbidities can be treated or untreated and should include either hypertension, dyslipidemia, or T2D.
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Wharton S, Blevins T, Connery L, et al; GZGI Investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. https://doi.org/10.1056/NEJMoa2302392
2A study of orforglipron (LY3502970) in adult participants with obesity or overweight with weight-related comorbidities (ATTAIN-1). ClinicalTrials.gov identifier: NCT05869903. Updated March 19, 2024. Accessed March 14, 2024. https://clinicaltrials.gov/study/NCT05869903
3A study of orforglipron in adult participants with obesity or overweight and type 2 diabetes (ATTAIN-2). ClinicalTrials.gov identifier: NCT05872620. Updated March 20, 2024. Accessed March 14, 2024. https://clinicaltrials.gov/study/NCT05872620
4A study of once-daily oral orforglipron (LY3502970) in japanese adult participants with obesity disease (ATTAIN-J). ClinicalTrials.gov identifier: NCT05931380. Updated March 4, 2024. Accessed March 14, 2024. https://clinicaltrials.gov/study/NCT05931380
Date of Last Review: March 14, 2024